Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Biprel; Coverex-AS KombForte; Coversyl Arginine Plus; Coversyl Plus; DW 7950; Indapamide/perindopril; Perigard-D; perindopril + indapamide; Predonium; Predonium DS; Preterax; S 5590

Latest Information Update: 23 Jun 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Class Antihypertensives; Indoles; Sulfonamides
  • Mechanism of Action ACE inhibitors; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 19 Jun 2008 Efficacy data from a Phase-III trial (ADVANCE) in Hypertension presented at the 18th European Meeting on Hypertension (ESH-2008)
  • 17 Oct 2006 CV Therapeutics has terminated its licence for perindopril/indapamide in the US
  • 31 Mar 2006 Launched for Hypertension in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top